GBA Presents: House of Gummy-!

stonedinvestor · Dec 6, 2023

It looks like what happened is I called the bottom in SNAP. Obviously the first call is the bottom.
Duh.
A stock falls and bottoms and and in this case retests but the first call in the face of the free fall is the brave one and the correct one!

So when a stock bottoms it is the first call that is the bottom.

Obviously CASE CLOSED

Van nailed the retest!

TrailerParkTed · Dec 6, 2023

Van called SHOT again, it’s $3.55 now. -25%

stonedinvestor · Dec 6, 2023

I won my picture at auction! Fisherman with a little penis really interesting-
it's made of labels.

TrailerParkTed · Dec 6, 2023

What’s WBUY? $11.51 down halt.

stonedinvestor · Dec 6, 2023

stonedinvestor said:
Verve director acquires $18M in company stock

Ok this is one of those they did a secondary but they got it off at $10 and a big buyer obviously was a director-- not the CEO.

I like this still $18 M is a big buy but in general these buys tied to secondaries can be seen as propping up the stk but that's usually 1 mil or 2... $10 is a commitment.

What wets the appetite is a recent sell off due to two deaths in trials---

Verve Therapeutics, Inc. (VERV) 30% on sale>
NasdaqGS - NasdaqGS Real Time Price.
12.22+0.65(+5.57%)<---------------------- Go Long/ Give it a try.
As of 09:50AM EST. Market open.

Gene editing and heart attacks
Verve is trying to build cutting-edge, gene-editing tools to help people deal with cardiovascular disease. Specifically, it hopes to commercialize its Verve-101 tool to edit human genes in people with naturally high LDL cholesterol (the bad cholesterol), which is correlated with heart disease. There are an estimated 3 million people in the United States and Europe affected by this condition, which indicates a potentially huge market for Verve if they can get this treatment commercialized.

This week, the company released some updated data for investors regarding a trial it is doing with the Verve-101 tool in humans. The market seems to be reacting to some concerning news with the 10 people Verve has trialed, as two of the patients died from heart attacks after receiving the treatment. Seeing this headline, the market reacted swiftly with investors likely concerned over the efficacy of this early-stage technology.

However, if we look under the hood, these heart attacks, from a research perspective, may not be as bad as they seem. Verve is purposefully looking for patients with extreme cardiovascular conditions, meaning they were already highly likely to have a heart attack before taking the drug. On a positive note, the trial indicates a 55% reduction in LDL levels for the patients, which is a huge improvement from current cholesterol-reduction methods.
More...

Out $13.12

stonedinvestor · Dec 6, 2023

It's odd for SCVL to be up so much especially with Designer Brands crashing yesterday.

It's not lie Shoe Carnival is doing well they warned recently. Wonder if this is M&A?

Shoe Carnival, Inc. (SCVL)-?
NasdaqGS - NasdaqGS Real Time Price.
26.90+2.06(+8.29%)<-----
As of 01:06PM EST.

TrailerParkTed · Dec 6, 2023

TrailerParkTed said:
What’s WBUY? $11.51 down halt.
More...

Shorts busted it from $13.90 to $9 on another halt. I don’t miss gambling.

stonedinvestor · Dec 6, 2023

Great Day everyone--!! Catch up tomorrow my wife has a big meeting at the apt I have to go in the back-- BLDR is the buy today!
PHR
Phreesia
$18.16
+3.48(+23.71%)

TrailerParkTed · Dec 6, 2023

stonedinvestor said:
Great Day everyone--!! Catch up tomorrow my wife has a big meeting at the apt I have to go in the back-- BLDR is the buy today!
PHR
Phreesia
$18.16
+3.48(+23.71%)
More...

Don’t get too wild!

stonedinvestor · Dec 6, 2023

11/8 these guys pulled their product and canceled 25% of the workforce--- stk get slew of downgrades...what are they up to now? Why the insider buying?

Rani Therapeutics CEO Talat Imran purchases 5,000 shares
SA NewsToday, 12:46 PM
Rani Therapeutics says CEO Imran buys 20K class A shares